Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

1361009

USP

Levodopa

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

3,4-Dihydroxy-L-phenylalanine, 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula linear:
(HO)2C6H3CH2CH(NH2)CO2H
Número CAS:
59-92-7
Peso molecular:
197.19
Beilstein:
2215169
Número MDL:
MFCD00002598
Código UNSPSC:
41116107
ID de substância PubChem:
329750042
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

levodopa

fabricante/nome comercial

USP

pf

276-278 °C (lit.)

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

chave InChI

WTDRDQBEARUVNC-LURJTMIESA-N

Informações sobre genes

human ... DRD3(1814)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Levodopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Outras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H315,H319,H335

Classificações de perigo

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órgãos-alvo

Respiratory system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 4

1 of 4

Carbidopa British Pharmacopoeia (BP) Reference Standard

BP060

Carbidopa

Benserazide hydrochloride European Pharmacopoeia (EP) Reference Standard

B0477000

Benserazide hydrochloride

Benserazide hydrochloride British Pharmacopoeia (BP) Reference Standard

BP685

Benserazide hydrochloride

Benserazide hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B7283

Benserazide hydrochloride

Damian M Herz et al.
Annals of neurology, 75(6), 829-836 (2014-06-04)
In Parkinson disease (PD), long-term treatment with the dopamine precursor levodopa gradually induces involuntary "dyskinesia" movements. The neural mechanisms underlying the emergence of levodopa-induced dyskinesias in vivo are still poorly understood. Here, we applied functional magnetic resonance imaging (fMRI) to
Pol Nadal-Jimenez et al.
Journal of bacteriology, 196(14), 2681-2690 (2014-05-13)
The iron binding siderophore pyoverdine constitutes a major adaptive factor contributing to both virulence and survival in fluorescent pseudomonads. For decades, pyoverdine production has allowed the identification and classification of fluorescent and nonfluorescent pseudomonads. Here, we demonstrate that PvdP, a
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
Lukas L Imbach et al.
Parkinsonism & related disorders, 20(11), 1283-1286 (2014-09-28)
Diagnosis and treatment of tremor are largely based on clinical assessment. Whereas in some patients tremor may respond to dopaminergic treatment, in general l-Dopa response to tremor varies considerably. The aim of this study was to predict l-Dopa response by
Vincent J J Odekerken et al.
Neurology, 84(13), 1355-1361 (2015-03-01)
To assess the neuropsychological outcome 12 months after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN) for advanced Parkinson disease. We randomly assigned patients to receive either GPi DBS or STN DBS.
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica